Advertisement

Topics

XBIOTECH Company Profile

05:37 EDT 22nd June 2018 | BioPortfolio

Nil

Contact

Phone: 41(0)44 789 98 46
Email: info@xbiotech.ch


News Articles [15 Associated News Articles listed on BioPortfolio]

XBiotech, Inc: XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer

Agreement Centers on XBiotech's Proprietary Manufacturing Technology to Advance Anti-NY-ESO-1 Antibody 12D7 AUSTIN, Texas, April 02, 2018 (GLOBE NEWSWIRE) -- XBiotech USA, Inc. (NASDAQ:XBIT) annou...

XBiotech, Inc: XBiotech veröffentlicht Ergebnisse für seinen auf S. aureus abzielenden True-Human-Antikörper 514G3 in PLOS ONE

Bericht dokumentiert die Fähigkeit von 514G3, Mäuse gegen tödliche S.-aureus-Bakteriämie-Infektionen zu schützen AUSTIN, Texas (USA), 25. Januar 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XB...

XBiotech, Inc: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology

XBiotech to Launch Two Phase 2 Clinical Studies to Study Subcutaneous Administration of MABp1 for Treatment of Hidradenitis Suppurativa and Atopic Dermatitis AUSTIN, Texas, April 16, 2018 (GLOBE N...

XBiotech, Inc: XBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa

Data Presented at the 7th Conference of the European Hidradenitis Suppurativa Foundation (EHSF) Provide Results that Corroborate HiSCR findings with iHS4 Scoring as a Measure of Efficacy AUSTIN, Te...

Active-Investors: Blog Exposure - XBiotech To Present Data From Phase-2 Study On MABp1 For Treatment Of Hidradenitis Suppurativa at EHSF Conference

LONDON, UK / ACCESSWIRE / January 29, 2018 / Active-Investors.com has just released a free research report on XBiotech Inc. (NASDAQ: XBIT). If you want access to this report all you need to do is s...

XBiotech, Inc: XBiotech präsentiert Daten der Phase-2-Studie zur Untersuchung von MABp1 für die Behandlung von Hidradenitis suppurativa

Die auf der 7. Konferenz der European Hidradenitis Suppurativa Foundation (EHSF) präsentierten Daten zeigen Ergebnisse, die die HiSCR-Ergebnisse mit dem iHS4-Scoring-System als Maß für die Wirksam....

XBiotech USA, CTA Sign License Agreement

For the advancement and the development of the True HumanTM anti-NY-ESO-1 monoclonal antibody, 12D7

XBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureus

Report Documents 514G3's Ability to Protect Mice Against Deadly S. aureus Bacteremia Infections AUSTIN, Texas, Jan. 25, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

More Information about "XBIOTECH" on BioPortfolio

We have published hundreds of XBIOTECH news stories on BioPortfolio along with dozens of XBIOTECH Clinical Trials and PubMed Articles about XBIOTECH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of XBIOTECH Companies in our database. You can also find out about relevant XBIOTECH Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record